Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: An analysis of pooled data

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 431-438

  Bleecker, Eugene R ^a   Siler, Thomas ^b   Owen, Roger ^c   Kramer, Benjamin ^d  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b Midwest Chest Consultants   (United States)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Tolerability

Indexed keywords

GLUCOSE; INDACATEROL; PLACEBO; POTASSIUM; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; BRONCHITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PULSE PRESSURE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SORE THROAT; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; AGED; DRUG ADMINISTRATION; DRUG EFFECT; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856597528     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S21073     Document Type: Article

References (39)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2010. Available from: http:// www.goldcopd.com. Accessed March 17, 2011.
2. Centers for Disease Control and Prevention (CDC). Deaths from chronic obstructive pulmonary disease - United States, 2000-2005. MMWR Morb Mortal Wkly Rep. 2008;57:1229-1232.
3. Centers for Disease Control and Prevention (CDC). Summary health statistics for US adults: National Health Interview Survey, 2008. Vital and Health Statistics [serial on the Internet]. Series 10, Number 242. December 2009. Available from: http://www.cdc.gov/nchs/data/series/ sr_10/sr10_242.pdf. Accessed May 12, 2010.
4. Thompson WH, St-Hilaire S. Prevalence of chronic obstructive pulmonary disease and tobacco use in veterans at Boise veterans affairs medical center. Respir Care. 2010;55:555-560.
5. Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82.
6. Barr RG, Celli BR, Mannino DM, et al. Co morbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122:348-355.
7. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J. 2004;23:932-946. Erratum in: Eur Respir J. 2006;27:242.
8. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med. 2010;10:11.
9. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax. 2010;65:473-479.
10. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182: 155-162.
11. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010;23:165-171.
12. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
13. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416-469.
14. Connolly CK. Diurnal rhythms in airway obstruction. Br J Dis Chest. 1979;73:357-366.
15. Dawkins KD, Muers MF. Diurnal variation in airflow obstruction in chronic bronchitis. Thorax. 1981;36:618-621.
16. Petty TL. Circadian variations in chronic asthma and chronic obstructive pulmonary disease. Am J Med. 1988;85:21-23.
17. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58:855-860.
18. Ramsdale EH, Morris MM, Hargreave FE. Interpretation of the variability of peak fow rates in chronic bronchitis. Thorax. 1986;41: 771-776.
19. Meurs H, Postma DS, Koëter GH, et al. The beta-adrenergic system of non-allergic patients with chronic airflow obstruction and early morning dyspnoea. Ann Allergy. 1987;59:417-421.
20. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25:2043-2048.
21. Casaburi R, Mahler DA, Jones P W, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
22. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404. Erratum in: Thorax. 2005;60:105.
23. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airfow in patients with COPD. Eur Respir J. 2006;27:547-555. Erratum in: Eur Respir J. 2006;27:1076.
24. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
25. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397-404.
26. Kornmann O, Dahl R, Centanni S, et al; For INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37:273-279.
27. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term safety and efficacy of indacaterol, a novel long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68-75.
28. Tsagaraki V, Amflochiou A, Markantonis SL. Evidence of tachy-phylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract. 2006;60:415-421.
29. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912-919. Erratum in: Eur Respir J. 2004;24:1075.
30. Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010;36:96-104.
31. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011. Epub ahead of print. doi: http://dx.doi.org/10.1183/09031936.00191810
32. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; For the INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105:719-726.
33. Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1995;152:580-588.
34. James PN, Anderson JB, Prior JG, White J P, Henry JA, Cochrane GM. Patterns of drug taking in patients with chronic airflow obstruction. Postgrad Med J. 1985;61:7-10.
35. Corden ZM, Bosley CM, Rees PJ, Cochrane GM. Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. Chest. 1997;112:1278-1282.
36. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
37. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101:1398-1405.
38. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101:1895-1902.
39. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831-838.